Compass Therapeutics, Inc. (CMPX)Healthcare | Biotechnology | Boston, United States | NasdaqCM
6.00 USD
-0.53
(-8.116%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 6.00 +0.00 (0.003%) ⇧ (April 17, 2026, 7:47 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:44 p.m. EDT
Despite the negative fundamentals and high-beta risk of a pre-revenue biotech with negative earnings, the market is rallying on specific clinical trial milestones (CTX-10726). The options chain acts as a clear contrarian signal to the short-seller crowd; with massive call volume at the 8.0 strike and analysts averaging $13.64, a short-term breakout above the 50-day average is the most probable near-term play, assuming the earnings estimate next month does not derail the momentum. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.109784 |
| AutoARIMA | 0.111249 |
| AutoETS | 0.111309 |
| AutoTheta | 0.139324 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 23.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.147 |
| Excess Kurtosis | -1.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.995 |
| Market Cap | 1,080,527,488 |
| Forward P/E | -12.44 |
| Beta | 1.30 |
| Website | https://www.compasstherapeutics.com |
As of April 18, 2026, 10:44 p.m. EDT: Options flow reveals a strong bullish bias. Call volume significantly outpaces put volume in near-term expirations (April, May). Specifically, massive call volume (27k) accumulated at the 8.0 SR, which represents a +33.3% upside from the current ~6.0 price. Despite high implied volatility for upside strikes (Bull Put Spread/Leverage), the speculation is heavily skewed towards calls. Put activity is concentrated in lower strikes (3.0, 4.0, 5.0) suggesting a floor defense below 5.0, whereas the majority of aggressive positioning targets the 6.0-8.0 range.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.3707864 |
| Address1 | 80 Guest Street |
| Address2 | Suite 601 |
| All Time High | 11.0 |
| All Time Low | 0.765 |
| Ask | 7.55 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 3,366,060 |
| Average Daily Volume3 Month | 2,324,469 |
| Average Volume | 2,324,469 |
| Average Volume10Days | 3,366,060 |
| Beta | 1.3 |
| Bid | 4.73 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.104 |
| City | Boston |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.0 |
| Current Ratio | 15.021 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.67 |
| Day Low | 5.87 |
| Debt To Equity | 4.995 |
| Display Name | Compass Therapeutics |
| Earnings Call Timestamp End | 1,754,913,600 |
| Earnings Call Timestamp Start | 1,754,913,600 |
| Earnings Timestamp | 1,772,717,400 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -72,563,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -12.147 |
| Enterprise Value | 881,450,496 |
| Eps Current Year | -0.41077 |
| Eps Forward | -0.4825 |
| Eps Trailing Twelve Months | -0.42 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.697 |
| Fifty Day Average Change | 0.30299997 |
| Fifty Day Average Change Percent | 0.053185884 |
| Fifty Two Week Change Percent | 237.07864 |
| Fifty Two Week High | 6.88 |
| Fifty Two Week High Change | -0.8800001 |
| Fifty Two Week High Change Percent | -0.127907 |
| Fifty Two Week Low | 1.665 |
| Fifty Two Week Low Change | 4.335 |
| Fifty Two Week Low Change Percent | 2.6036036 |
| Fifty Two Week Range | 1.665 - 6.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,617,629,400,000 |
| Float Shares | 118,868,829 |
| Forward Eps | -0.4825 |
| Forward P E | -12.435233 |
| Free Cashflow | -26,161,376 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 39 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.111420006 |
| Held Percent Institutions | 0.87654 |
| Implied Shares Outstanding | 180,087,915 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-11-02 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts. |
| Long Name | Compass Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,080,527,488 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_266166780 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -66,489,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,079,627,050 |
| Number Of Analyst Opinions | 14 |
| Open | 6.6 |
| Operating Cashflow | -49,143,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 500 8099 |
| Post Market Change | 0.00019979477 |
| Post Market Change Percent | 0.003329913 |
| Post Market Price | 6.0002 |
| Post Market Time | 1,776,469,673 |
| Previous Close | 6.53 |
| Price Eps Current Year | -14.606714 |
| Price Hint | 2 |
| Price To Book | 5.434783 |
| Profit Margins | 0.0 |
| Quick Ratio | 14.956 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.1875 |
| Region | US |
| Regular Market Change | -0.53 |
| Regular Market Change Percent | -8.11639 |
| Regular Market Day High | 6.67 |
| Regular Market Day Low | 5.87 |
| Regular Market Day Range | 5.87 - 6.67 |
| Regular Market Open | 6.6 |
| Regular Market Previous Close | 6.53 |
| Regular Market Price | 6.0 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 3,731,736 |
| Return On Assets | -0.25292 |
| Return On Equity | -0.41294 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 180,087,915 |
| Shares Percent Shares Out | 0.1451 |
| Shares Short | 26,127,480 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 23,008,490 |
| Short Name | Compass Therapeutics, Inc. |
| Short Percent Of Float | 0.22760001 |
| Short Ratio | 12.39 |
| Source Interval | 15 |
| State | MA |
| Symbol | CMPX |
| Target High Price | 30.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 13.64286 |
| Target Median Price | 12.0 |
| Total Cash | 208,906,000 |
| Total Cash Per Share | 1.16 |
| Total Debt | 9,829,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.42 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.5695 |
| Two Hundred Day Average Change | 1.4305 |
| Two Hundred Day Average Change Percent | 0.31305397 |
| Type Disp | Equity |
| Volume | 3,731,736 |
| Website | https://www.compasstherapeutics.com |
| Zip | 2,135 |